ERBB activation modulates sensitivity to MEK1/2 inhibition in a subset of driver-negative melanoma

Area of Science:

• Oncology
• Molecular Biology
• Dermatology

Background:

• Melanomas often harbor driver mutations (BRAF, NRAS, KIT) activating the MAPK pathway, influencing treatment response.
• Driver-negative melanomas exhibit heterogeneous responses to MEK1/2 inhibitors, posing a clinical challenge.
• Understanding resistance mechanisms is crucial for developing targeted therapies for melanoma.

Purpose of the Study:

• To investigate the heterogeneity of MEK1/2 inhibitor response in driver-negative melanoma.
• To identify molecular mechanisms underlying differential sensitivity to MEK1/2 inhibitors.
• To explore potential therapeutic strategies for resistant melanoma subtypes.

Main Methods:

• Analysis of 16 driver-negative melanoma cell lines treated with trametinib.
• Characterization of signaling pathways (MAPK, PI3K/AKT, ERBB) in sensitive and resistant cell lines.
• Assessment of DUSP4 expression and its role in ERBB signaling modulation.
• Immunohistochemical analysis of DUSP4 in patient melanoma samples.

Main Results:

• 50% of driver-negative cell lines (Class I) were sensitive to trametinib, while 25% (Class II) showed reduced sensitivity.
• Class II melanomas exhibited paradoxical MEK1/2 activation and basal ERBB signaling.
• ERBB inhibition (afatinib) combined with trametinib abrogated signaling and reduced proliferation in Class II lines.
• Low DUSP4 expression was linked to ERBB activation in Class II melanomas, with a trend observed in patient tumors.

Conclusions:

• Differential ERBB pathway activity significantly modulates MEK1/2 inhibitor sensitivity in driver-negative melanoma.
• Minimal DUSP4 expression may contribute to ERBB activation and trametinib resistance.
• Combination therapy with ERBB and MEK1/2 inhibitors shows promise for treating specific subsets of driver-negative melanoma.